<abstract xmlns="http://www.w3.org/1999/xhtml"><p> The objectives of the study were to determine the efficacy of pegylated interferon alfa 2 b (PegINF) and ribavirin (RBV) treatment in co-infected HIV / HCV patients, to identify predictive factors associated with sustained viral response (SVR) in these patients. Out of the 956 HIV infected patients, 38 were HCVAb (4%) positive, 14 of which had undetectable HCV RNA, only 6 patients met the inclusion criteria. Screening failure was due to: liver cirrhosis Child Pugh B / C, hepatocellular carcinoma, pulmonary TB, thyroid dysfunction, CD4 &lt;200 cells3, detectable HIV RNA and depressive syndrome. We initiated PegINF and RBV therapy for 48 weeks. SVR was achieved in 16.6% of cases (only one patient) and correlated with HCV RNA level, CD4 count, duration of HIV infection, CDC classification and liver fibrosis. In conclusion, our study group has a low prevalence of HIV / HCV co-infection (2.6%) with a large number of patients HCVAb positive but undetectable HCV RNA. Positive predictive factors for SVR were: low levels of HCV RNA, small duration of HIV infection, high levels of CD4, B1/B2 (CDC classification) and low degree of fibrosis.</p></abstract>

The objectives of the study were to determine the efficacy of pegylated interferon alfa 2 b (PegINF) and ribavirin (RBV) treatment in co-infected HIV / HCV patients, to identify predictive factors associated with sustained viral response (SVR) in these patients. Out of the 956 HIV infected patients, 38 were HCVAb (4%) positive, 14 of which had undetectable HCV RNA, only 6 patients met the inclusion criteria. Screening failure was due to: liver cirrhosis Child Pugh B / C, hepatocellular carcinoma, pulmonary TB, thyroid dysfunction, CD4 <200 cells3, detectable HIV RNA and depressive syndrome. We initiated PegINF and RBV therapy for 48 weeks. SVR was achieved in 16.6% of cases (only one patient) and correlated with HCV RNA level, CD4 count, duration of HIV infection, CDC classification and liver fibrosis. In conclusion, our study group has a low prevalence of HIV / HCV co-infection (2.6%) with a large number of patients HCVAb positive but undetectable HCV RNA. Positive predictive factors for SVR were: low levels of HCV RNA, small duration of HIV infection, high levels of CD4, B1/B2 (CDC classification) and low degree of fibrosis.

Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients

University “Ovidius” of Constanţa, Faculty of Medicine, Infectious Diseases Clinic,

University “Ovidius” of Constanţa, Faculty of Medicine, Gastroenterology Department,

University “Ovidius” of Constanţa, Faculty of Medicin, Nephrology Clinic,

University “Ovidius” of Constanţa, Faculty of Medicine, Infectious Diseases Clinic, AOSR (Academy scientists Romania),

ARS Medica Tomitana

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

The objectives of the study were to determine the efficacy of pegylated interferon alfa 2 b (PegINF) and ribavirin (RBV) treatment in co-infected HIV / HCV...

Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients

Publié en ligne: 22 avr. 2017

Pages: 47 - 52

DOI: https://doi.org/10.1515/arsm-2017-0009

Mots clés
HIV/ HCV coinfection, antiviral treatment, SVR

© by Eugen Dumitru

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients

Publié en ligne: 22 avr. 2017

Pages: 47 - 52

DOI: https://doi.org/10.1515/arsm-2017-0009

Mots clésHIV/ HCV coinfection, antiviral treatment, SVR

© by Eugen Dumitru

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Mots clés
HIV/ HCV coinfection, antiviral treatment, SVR